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Background
We evaluated the efficacy of raltegravir and the development of viral resistance in 
two identical trials involving patients who were infected with human immunodefi-
ciency virus type 1 (HIV-1) with triple-class drug resistance and in whom antiretro-
viral therapy had failed.
Methods
We conducted subgroup analyses of the data from week 48 in both studies accord-
ing to baseline prognostic factors. Genotyping of the integrase gene was performed 
in raltegravir recipients who had virologic failure.
Results
Virologic responses to raltegravir were consistently superior to responses to place-
bo, regardless of the baseline values of HIV-1 RNA level; CD4 cell count; genotypic 
or phenotypic sensitivity score; use or nonuse of darunavir, enfuvirtide, or both in 
optimized background therapy; or demographic characteristics. Among patients in the 
two studies combined who were using both enfuvirtide and darunavir for the first 
time, HIV-1 RNA levels of less than 50 copies per milliliter were achieved in 89% of 
raltegravir recipients and 68% of placebo recipients. HIV-1 RNA levels of less than 50 
copies per milliliter were achieved in 69% and 80% of the raltegravir recipients and 
in 47% and 57% of the placebo recipients using either darunavir or enfuvirtide for 
the first time, respectively. At 48 weeks, 105 of the 462 raltegravir recipients (23%) 
had virologic failure. Genotyping was performed in 94 raltegravir recipients with 
virologic failure. Integrase mutations known to be associated with phenotypic re-
sistance to raltegravir arose during treatment in 64 patients (68%). Forty-eight of 
these 64 patients (75%) had two or more resistance-associated mutations.
Conclusions
When combined with an optimized background regimen in both studies, a consis-
tently favorable treatment effect of raltegravir over placebo was shown in clinically 
relevant subgroups of patients, including those with baseline characteristics that typi-
cally predict a poor response to antiretroviral therapy: a high HIV-1 RNA level, low 
CD4 cell count, and low genotypic or phenotypic sensitivity score. (ClinicalTrials.gov 
numbers, NCT00293267 and NCT00293254.)
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Despite the substantial decrease in mortality and morbidity rates associated with highly active antiretroviral therapy 
over the past decade, there is still a substantial 
need for effective antiretroviral drugs for patients 
infected with resistant human immunodeficiency 
virus type 1 (HIV-1).1,2 The majority of licensed 
antiretroviral drugs belong to three classes tar-
geting either the HIV-1 protease or reverse tran-
scriptase, and considerable cross-resistance exists 
among drugs within each class.3,4 In patients with 
resistant virus, use of antiretroviral agents from 
new classes offers considerable potential benefit 
because of the absence of cross-resistance.5-7
HIV-1 integrase represents a new therapeutic 
target.8,9 Consequently, HIV-1 integrase inhibi-
tors would be expected to retain activity against 
HIV-1 that is resistant to other classes of anti-
retroviral drugs. Raltegravir (MK-0518; Isentress, 
Merck), an HIV integrase strand-transfer inhibitor, 
has exhibited substantial efficacy and a favor-
able safety profile in patients infected with 
HIV-1,7,10,11 including those with multidrug- 
resistant HIV-1 and a history of treatment failure.7,11 
In a phase 2 study of previously treated patients 
who had multidrug-resistant virus, mean decreas-
es in the viral load at week 24 ranged from 1.8 to 
1.9 log10 copies per milliliter in those receiving 
raltegravir at doses of 200, 400, or 600 mg twice 
daily in combination with optimized background 
therapy, as compared with 0.4 log10 copies per 
milliliter in those receiving optimized back-
ground therapy alone; in approximately 60% of 
patients receiving raltegravir, as compared with 
13% of patients receiving placebo, HIV-1 RNA 
levels were reduced to less than 50 copies per 
milliliter.7 These findings were confirmed in 
both phase 3 BENCHMRK-1 and BENCHMRK-2 
studies (Blocking Integrase in Treatment Experi-
enced Patients with a Novel Compound against 
HIV, Merck studies).11 In this report, we present 
the results of subgroup efficacy analyses and the 
evaluation of virologic resistance to raltegravir in 
patients with virologic failure, using data from 
week 48 from the combined BENCHMRK-1 and 
BENCHMRK-2 studies.
Me thods
The studies were designed, managed, and ana-
lyzed by the sponsor in conjunction with the aca-
demic authors. The authors had access to all study 
data on request. This report was principally 
drafted by two academic authors and four indus-
try authors and was critically reviewed and ap-
proved by all the authors in its final form before 
submission. All authors vouch for the complete-
ness and accuracy of the data.
Study Design
The identical study design of BENCHMRK-1 and 
BENCHMRK-2, criteria for scoring the activity of 
optimized background therapy, and the overall 
evaluation of efficacy are described in detail in 
the article by Steigbigel et al. in this issue of the 
Journal.11 The subgroup efficacy analyses includ-
ed complete 48-week data from both studies. The 
potential emergence of resistance to raltegravir 
was investigated in patients with virologic failure 
by genotyping the integrase coding sequence. The 
integrase gene was reverse-transcribed from plas-
ma HIV-1 RNA and sequenced according to stan-
dard methods. Consensus amino acid sequences 
were compared with pretreatment genotypes.
Statistical Analysis
Because BENCHMRK-1 and BENCHMRK-2 shared 
the same study design and showed consistent 
treatment effects, a combined analysis and ex-
ploratory subgroup analyses of pooled data from 
the two studies were undertaken. Subgroup analy-
ses based on potential prognostic factors were 
prespecified (except for the combination of enfu-
virtide and darunavir in optimized background 
therapy) before unblinding of the data. The pheno-
typic and genotypic sensitivity scores are the to-
tal number of antiretroviral drugs used as part of 
the optimized background therapy to which a pa-
tient’s HIV was fully susceptible, as determined 
with the use of phenotypic and genotypic resis-
tance testing, respectively. Enfuvirtide use in op-
timized background therapy in patients who had 
not previously received enfuvirtide was counted 
as one active drug in optimized background 
therapy and added to the genotypic and pheno-
typic sensitivity scores. Darunavir use in opti-
mized background therapy in patients who had 
not previously received darunavir was likewise 
counted as one active drug and added to the phe-
notypic and genotypic sensitivity scores. In addi-
tion, darunavir use in optimized background 
therapy in patients who had not previously re-
ceived darunavir was counted as one active pro-
tease inhibitor.
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Prognostic factors, such as baseline HIV-1 RNA 
levels and the genotypic and phenotypic sensitiv-
ity scores for optimized background therapy, 
may be strongly associated with virologic and 
immunologic responses but are less likely to be 
associated with adverse events or discontinuation 
for reasons not related to treatment. Because it 
predominantly reflects the antiretroviral effect 
of treatment, an observed-failure approach (in 
which only patients who discontinued the study 
because of lack of efficacy were considered to 
have treatment failure at subsequent time points) 
was used as the basis of the exploratory sub-
group analyses.7 Differences (and the 95% con-
fidence intervals) between treatment groups in 
the proportion of patients with HIV-1 RNA levels 
below 50 copies per milliliter and in the mean 
change from the baseline CD4 cell counts were 
calculated for both the overall study groups and 
subgroups of interest.11
R esult s
Characteristics of the Patients
A total of 699 patients were treated in BENCH-
MRK-1 and BENCHMRK-2: 462 patients received 
raltegravir and 237 received placebo. Baseline 
characteristics were generally balanced between 
the treatment groups within each study.11 Table 
1 lists selected baseline characteristics that have 
been identified as factors potentially affecting 
the efficacy of antiretroviral therapy. These cova-
riates include the baseline HIV-1 RNA level and 
CD4 cell count; the use or nonuse of newly avail-
able antiretroviral drugs such as enfuvirtide, 
darunavir, and tipranavir as part of optimized 
background therapy; the number of active protease 
inhibitors used in optimized background thera-
py; and the number of active drugs in optimized 
background therapy, as measured by the pheno-
typic or genotypic sensitivity score at baseline.
Baseline HIV-1 RNA levels were greater than 
100,000 copies per milliliter in 35% of raltegra-
vir recipients and 33% of placebo recipients. 
Baseline CD4 cell counts were 50 or less per 
cubic millimeter in 32% and 33% of raltegravir 
and placebo recipients, respectively. The median 
number of antiretroviral drugs in the optimized 
background therapy was four in both treatment 
groups. Despite this aggressive treatment, 36% 
of patients in the raltegravir group and 41% of 
patients in the placebo group had no fully active 
protease inhibitors in their optimized back-
ground therapy. The genotypic sensitivity score 
of the optimized background therapy was 0 in 
25% of patients receiving raltegravir and in 27% 
of patients receiving placebo. The phenotypic 
sensitivity score of the optimized background 
therapy was 0 in 15% of raltegravir recipients 
and in 19% of placebo recipients.
Subgroup Efficacy Analyses
As reported in the article by Steigbigel et al.,11 
the overall virologic and immunologic responses 
in the raltegravir groups were superior to those 
in the placebo groups after 16 weeks and 48 
weeks of treatment. At week 48, in the analysis in 
which noncompletion constituted treatment fail-
ure, 72% of patients in the raltegravir groups, as 
compared with 37% of patients in the placebo 
groups, had HIV-1 RNA levels below 400 copies 
per milliliter (P<0.001), and 62% of patients in 
the raltegravir groups, as compared with 33% of 
patients in the placebo groups, had HIV-1 RNA 
levels below 50 copies per milliliter (P<0.001). 
Similar results were seen in the analyses that 
used the observed-failure approach.
In subgroup analyses involving selected base-
line prognostic factors and demographic charac-
teristics based on the observed-failure approach, 
raltegravir recipients had higher virologic and 
immunologic response rates than placebo re-
cipients across most subgroups, including pa-
tients with baseline HIV-1 RNA levels of more 
than 100,000 copies per milliliter and CD4 cell 
counts of less than 50 per cubic millimeter (Fig. 1). 
In patients receiving optimized background 
therapy with a genotypic sensitivity score of 0, 
HIV-1 RNA levels of less than 50 copies per milli-
liter were achieved at week 48 in 45% of patients 
receiving raltegravir as compared with 3% of 
those receiving placebo, and the mean changes 
in the CD4 cell count between baseline and week 
48 were 81 and 11 per cubic millimeter, respec-
tively (Fig. 2). Among patients with more active 
optimized background therapy, reflected by a 
genotypic sensitivity score of 2, 77% of raltegra-
vir recipients had HIV-1 RNA levels below 50 cop-
ies per milliliter at week 48, as compared with 
62% of placebo recipients; the corresponding 
mean changes in the CD4 cell count were 145 
and 87 per cubic millimeter, respectively. Similar 
findings were observed in the subgroup analysis 
based on the phenotypic sensitivity score. Only 
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Male 405 (88) 210 (89)
Female 57 (12) 27 (11)
Race or ethnic group†
White 300 (65) 173 (73)
Black 66 (14) 26 (11)
Asian 16 (3) 6 (3)
Hispanic 53 (11) 19 (8)
Other 27 (6) 13 (5)
Region
North America 192 (42) 99 (42)
South America 61 (13) 31 (13)
Asia or Australia 38 (8) 20 (8)
Europe 171 (37) 87 (37)
Viral subtype
Clade B 415 (90) 219 (92)
Other 39 (8) 15 (6)
Missing data 8 (2) 3 (1)
Plasma HIV-1 RNA level
≤50,000 copies/ml 217 (47) 125 (53)
>50,000 and ≤100,000 copies/ml 81 (18) 34 (14)
>100,000 copies/ml 164 (35) 78 (33)
CD4 cell count
≤50/mm3 146 (32) 78 (33)
>50 and ≤200/mm3 173 (37) 85 (36)
>200/mm3 142 (31) 74 (31)
Missing data 1 (<1) 0
Enfuvirtide use in OBT
No 287 (62) 148 (62)
Yes, in those who had previously used enfuvirtide 83 (18) 41 (17)
Yes, in those who had not used enfuvirtide 92 (20) 48 (20)
Darunavir use in OBT
No 278 (60) 138 (58)
Yes, in those who had previously used darunavir 18 (4) 9 (4)
Yes, in those who had not used darunavir 166 (36) 90 (38)
Tipranavir use in OBT
No 364 (79) 193 (81)
Yes
By phenotypic test
HIV-1 resistant to tipranavir 41 (9) 19 (8)
HIV-1 sensitive to tipranavir 53 (11) 25 (11)
Missing data 4 (1) 0
By genotypic test
HIV-1 resistant to tipranavir 44 (10) 22 (9)
HIV-1 sensitive to tipranavir 53 (11) 22 (9)
Missing data 1 (<1) 0
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in the relatively few patients whose optimized 
background therapy was associated with a geno-
typic or phenotypic sensitivity score of 3 or more 
was the treatment advantage of raltegravir over 
placebo not strikingly evident.
Additional analyses were conducted to evalu-
ate the effect of newly available antiretroviral 
drugs (darunavir or enfuvirtide used alone or in 
combination, and tipranavir) as part of opti-
mized background therapy. Among patients re-
ceiving both enfuvirtide and darunavir for the 
first time, 89% of patients in the raltegravir 
groups and 68% of patients in the placebo 
groups had HIV-1 RNA levels of less than 50 
copies per milliliter at week 48 (Fig. 3), with 
corresponding changes in the CD4 cell count of 
129 and 81 per cubic millimeter, respectively 
(Fig. 1 in Supplementary Appendix 2, available 
with the full text of this article at www.nejm.
org). HIV-1 RNA levels below 50 copies per mil-
liliter were achieved in 69% and 80% of the 
raltegravir recipients as compared with 47% and 
57% of the placebo recipients using either daru-
navir or enfuvirtide for the first time, respective-
ly, and the changes in CD4 cell count were 114 
and 116 per cubic millimeter among raltegravir 
recipients as compared with 74 and 49 per cubic 
millimeter among placebo recipients, respectively.
Raltegravir recipients had higher response 
rates than placebo recipients, whether or not 
tipranavir was used in the optimized back-
ground therapy.12 In patients treated with tipra-
navir who had virus that was genotypically sen-
sitive to tipranavir, HIV-1 RNA levels were 
reduced to less than 50 copies per milliliter in 
73% of raltegravir recipients, as compared with 
40% of placebo recipients (Fig. 3). The mean 
changes in the CD4 cell count in this subgroup 
were 114 and 56 per cubic millimeter, respec-
tively (Fig. 1 in Supplementary Appendix 2). In 
patients treated with tipranavir as part of their 
optimized background therapy who had virus 
that was genotypically resistant to tipranavir, 
36% of raltegravir recipients, as compared with 
15% of placebo recipients, had HIV-1 RNA levels 
of less than 50 copies per milliliter; the corre-
sponding mean changes in the CD4 count were 








No. of active protease inhibitors in OBT (by phenotypic test)‡
0 168 (36) 98 (41)
≥1 278 (60) 137 (58)
Missing data 16 (3) 2 (1)
Phenotypic sensitivity score§
0 69 (15) 44 (19)
1 145 (31) 72 (30)
2 142 (31) 66 (28)
≥3 85 (18) 48 (20)
Missing data 21 (5) 7 (3)
Genotypic sensitivity score§
0 115 (25) 66 (28)
1 178 (39) 96 (41)
2 111 (24) 49 (21)
≥3 51 (11) 23 (10)
Missing data 7 (2) 3 (1)
* OBT denotes optimized background therapy.
† Race or ethnic group was self-reported.
‡ Darunavir in OBT in patients who had not previously received darunavir was counted as one active protease inhibitor.
§ First use of enfuvirtide in OBT was counted as one active drug and added to the phenotypic and genotypic sensitivity 
scores. First use of darunavir in OBT was counted as one active drug and added to the phenotypic and genotypic sensi-
tivity scores.
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Additional efficacy analyses based on sex, 
race or ethnic group, geographic region, and viral 
subtype consistently showed higher response 
rates in the raltegravir groups than in the pla-
cebo groups, in terms of viral-load reductions 
(Fig. 4) as well as increases in the CD4 cell count 
(Fig. 2 in Supplementary Appendix 2).
Resistance Mutations in the Integrase Gene
A total of 105 of the 462 patients receiving ralteg-
ravir (23%) had virologic failure by week 48. In-
tegrase genotyping had been performed both at 
baseline and after virologic failure in 94 of these 
105 patients (90%) at the time of this analysis; 64 
of the 94 patients (68%) had genotypic evidence 
of viral resistance to raltegravir when tested at 
the time of, or shortly after, viral rebound (Table 
2). Of the 64 patients with integrase mutations 
previously associated with phenotypic raltegravir 
resistance, 48 (75%) had two or more such muta-
tions. Virologic failure was generally associated 
with mutations at one of three residues — Y143, 
Q148, or N155 — usually in combination with 
at least one other mutation (Table 2). The risk 
of mutations arising during treatment was in-
creased in patients with higher baseline HIV-1 
RNA levels or receiving optimized background 
therapy with a genotypic or phenotypic sensitivity 
score of 0.
Discussion
The results of the BENCHMRK-1 and BENCH-
MRK-2 studies showed the consistently superior 
efficacy of raltegravir over placebo when used in 
combination with optimized background ther-
apy.11 Substantial viral-load suppression and in-
creases in CD4 cell counts as compared with the 
baseline values were sustained for at least 48 
weeks. The absolute response rate in the com-
bined placebo groups (33% of patients having 
<50 HIV-1 RNA copies per milliliter) was better 
33p9
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Figure 1. Percentages of Patients with HIV-1 RNA Levels of Less Than 50 Copies per Milliliter at Week 48, According to 
Subgroup.
The vertical dashed line represents the overall treatment-effect estimate. OBT denotes optimized background therapy.
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than that in a phase 2 study of raltegravir (13% 
with <50 HIV-1 RNA copies per milliliter),7 most 
likely reflecting the permitted use of investiga-
tional or recently licensed antiretroviral drugs in 
optimized background therapy in the BENCH-
MRK studies. The response rate in the placebo 
groups in these studies was consistent with the 
45% response rate reported previously among 
similar patients receiving darunavir.13
The BENCHMRK studies were not powered to 
show significant effects within subgroups.14 Al-
though there may have been imbalances within 
each subgroup in other prognostic factors be-
tween the raltegravir groups and the placebo 
groups, the subgroup analyses consistently 
showed a treatment advantage of raltegravir over 
placebo when given in combination with opti-
mized background therapy. Specifically, ralteg-
ravir was more efficacious than placebo, regard-
less of baseline prognostic factors. Overall, patients 
with lower baseline HIV-1 RNA levels or higher 
baseline CD4 cell counts had higher response 
rates than patients with higher baseline HIV-1 
RNA levels or lower baseline CD4 cell counts; 
however, the differences in treatment effect be-
tween the raltegravir and placebo groups were 
consistent in direction and magnitude in these 
subgroups. These findings are similar to those 
from the T-20 vs. Optimized Regimen Only Stud-
ies (TORO-1 and TORO-2) of enfuvirtide.5,6,15
As found in the phase 2 trial of raltegravir in 
previously treated patients infected with a multi-
drug-resistant virus,7 raltegravir had superior 
efficacy as compared with placebo in patients 
receiving optimized background therapy with a 
genotypic or phenotypic sensitivity score of 0, 
which is generally regarded as the most challeng-
ing treatment scenario. Nonetheless, functional 
monotherapy with raltegravir (in which there are 
no fully active drugs in the optimized back-
33p9




























Difference in Mean Change (95% CI)
Mean Change in CD4 Cell Count 
from Baseline (95% CI)
Raltegravir groups Placebo groups
cells/mm3 cells/mm3
109 (98 to 121)  
84 (69 to 100)
132 (115 to 148)
100 (86 to 115)  
126 (107 to 144)
121 (100 to 142)
104 (88 to 119)  
104 (80 to 129)  
85 (68 to 101)
124 (108 to 140)
71 (47 to 96)  
111 (86 to 135)  
119 (102 to 137)
119 (90 to 148)  
81 (55 to 106)
113 (96 to 130)  
145 (122 to 168)
79 (43 to 115)
  45 (32 to 57)  
48 (28 to 68)
41 (26 to 56)
49 (33 to 65)
36 (17 to 55)
33 (18 to 48)
47 (28 to 66)
54 (24 to 84)
12 (0 to 24)  
69 (50 to 88)
  11 (−10 to 32)
51 (23 to 78)
42 (20 to 63)
66 (38 to 95)
11 (−4 to 26)
44 (24 to 63)
  87 (49 to 125)
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Figure 2. Mean Changes in CD4 Cell Count between Baseline and Week 48, According to Subgroup.
The vertical dashed line represents the overall treatment-effect estimate. OBT denotes optimized background therapy.
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ground therapy) should be avoided whenever 
possible, given the greater absolute response 
rates among patients with more active optimized 
background therapy (defined as genotypic or 
phenotypic sensitivity score >0) as well as the 
lower risk of virologic failure and development 
of resistance in patients receiving more active 
optimized background therapy. For example, in 
33p9
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Placebo Better Raltegravir Better
Total
Use of enfuvirtide or darunavir in OBT
First use of enfuvirtide and darunavir
First use of enfuvirtide; no use of darunavir
First use of darunavir; no use of enfuvirtide
No use of enfuvirtide or darunavir
Use of tipranavir in OBT
No
Yes, HIV-1 resistant to tipranavir (by phenotypic test)
Yes, HIV-1 sensitive to tipranavir (by phenotypic test)
Yes, HIV-1 resistant to tipranavir (by genotypic test)
Yes, HIV-1 sensitive to tipranavir (by genotypic test)
Difference in Response RatesResponse Rates
Raltegravir groups Placebo groups
















  67/188 (36)
  4/18 (22)
  7/22 (32)
  3/20 (15)
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Figure 3. Percentages of Patients with HIV-1 RNA Levels of Less Than 50 Copies per Milliliter at Week 48, According to Use or Nonuse  
of Selected Antiretroviral Drugs.
The vertical dashed line represents the overall treatment-effect estimate. Data from patients treated with enfuvirtide or darunavir as part 
of their optimized background therapy were excluded from this analysis if they had previously been treated with enfuvirtide or darunavir, 
respectively. OBT denotes optimized background therapy.
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Figure 4. Percentages of Patients with HIV-1 RNA Levels of Less Than 50 Copies per Milliliter at Week 48, According to 
Demographic Characteristics and Viral Subtype.
Race or ethnic group was self-reported. The vertical dashed line represents the overall treatment-effect estimate.
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89% of patients receiving raltegravir along with 
enfuvirtide and darunavir for the first time in 
their optimized background therapy, HIV-1 RNA 
levels were reduced to less than 50 copies per 
milliliter. This substantial rate of viral suppres-
sion, which approaches the rates reported among 
patients infected with HIV who have not been 
previously treated,16 is remarkable for patients 
infected with virus that has triple-class drug 
resistance and in whom therapy has failed previ-
ously. The BENCHMRK studies, along with 
other recently reported studies,13,17 indicate that 
suppressing the viral load to less than 50 copies 
per milliliter is an attainable goal, even in heav-
ily pretreated patients infected with virus that 
has multiclass drug resistance.
In healthy volunteers, coadministration of 
raltegravir with tipranavir reduced nadir levels 
of raltegravir by 55%.12 Therefore, a detailed 
analysis of tipranavir use in the phase 3 BENCH-
MRK studies was undertaken to evaluate the 
potential effect on the efficacy of raltegravir. 
Among patients who received tipranavir as part 
of optimized background therapy in both the 
raltegravir and the placebo groups, those with 
tipranavir-resistant virus had lower response 
Table 2. HIV-1 Integrase Mutations Arising during the Treatment Period in 94 Patients in the Raltegravir Group with Virologic Failure  
by Week 48.*









0 (N = 49) 1 (N = 27) ≥2 (N = 18)
number of patients (percent)
Mutation known to confer raltegravir resistance§ 64 (68) 38 (78) 20 (74) 6 (33)
No amino acid changes from baseline sequence 25 (27) 9 (18) 6 (22) 10 (56)
Amino acid changes of unknown phenotypic 
effect¶
5 (5) 2 (4) 1 (4) 2 (11)
Specific mutation
At amino acid 148, 155, or 143 8 (62) 54 (67)
Amino acid 148 3 (23) 24 (30)
Q148H 1 (8) 12 (15)
Q148K 1 (8) 4 (5)
Q148R 1 (8) 14 (17)
Amino acid 155 3 (23) 35 (43)
Amino acid 143 2 (15) 8 (10)
No mutation at amino acid 148, 155, or 143 5 (38) 27 (33)
Other raltegravir-resistance mutation‖ 0 2 (2)
Amino acid changes of unknown phe-
notypic effect¶
1 (8) 4 (5)
No amino acid changes from baseline 
sequence
4 (31) 21 (26)
* Of the 462 raltegravir recipients, 105 (23%) had virologic failure by week 48; of these, 94 (89%) had genotyping results available at both 
baseline and the time of virologic failure and were included in this analysis. Four patients for whom only baseline genotypes were available 
were not included.
† A lack of response was defined as an HIV RNA log10 level that was not reduced by more than 1.0, or that was not suppressed to less than 
400 copies per milliliter, by week 16.
‡ Viral rebound was defined at or after week 16 as an HIV-1 RNA level of more than 400 copies per milliliter (in two consecutive measure-
ments at least 1 week apart) after an initial reduction to less than 400 copies per milliliter, or an increase of more than 1.0 log10 HIV RNA 
level above the nadir level (on two consecutive measurements at least 1 week apart).
§ Integrase mutations were N155H, Q148H, Q148K, Q148R, Y143C, Y143R, or E92Q, usually in combination with other mutations.
¶ Four patients had a single amino acid change (I203M in three and G163R in one), and one other patient had multiple changes (S24N, 
M50I, G70D, and L234I); these mutations have not yet been tested in phenotypic assays.
‖ One patient had the E92E/Q mixture, and one had the L74M and E92Q mutations.
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rates than those with tipranavir-sensitive virus, 
presumably owing to the lack of an active pro-
tease inhibitor in the tipranavir-based optimized 
background therapy. In patients with tipranavir-
sensitive virus, the use of tipranavir as part of 
optimized background therapy did not appear to 
negate the favorable treatment effect in the ral-
tegravir groups.
Sex, race or ethnic group, geographic region, 
and viral subtype (clade B vs. other clades) ap-
parently did not affect overall efficacy. Subgroup 
analyses according to sex, race or ethnic group, 
geographic region, and viral subtype showed gen-
erally higher response rates for raltegravir recipi-
ents than for placebo recipients, but more research 
is necessary to confirm these observations.
The limited genotypic-resistance data avail-
able to date support the in vitro findings that 
more than one integrase mutation is generally 
observed in HIV strains that become resistant to 
raltegravir.9 Genotypic resistance to raltegravir 
was anticipated in patients who had virologic 
failure in the raltegravir groups, especially in 
those who received raltegravir as functional 
monotherapy. Consequently, as recommended in 
formal treatment guidelines for all antiretroviral 
drugs,1,2 raltegravir should be used in combina-
tion with at least one other active antiretroviral 
agent whenever possible to minimize the devel-
opment of resistance and the risk of virologic 
failure. Long-term efficacy data, beyond 48 weeks, 
particularly in patients receiving optimized back-
ground therapy with genotypic and phenotypic 
sensitivity scores of 0, will aid in the interpreta-
tion of specific integrase mutations and their 
contribution to the development of resistance to 
raltegravir.
In summary, treatment with raltegravir in 
combination with optimized background thera-
py, as compared with optimized background ther-
apy alone, resulted in significant virologic and 
immunologic benefits for at least 48 weeks in 
both international BENCHMRK studies. The sub-
group analyses presented here show a consis-
tently favorable treatment effect of raltegravir, 
regardless of viral load, CD4 cell count, and 
genotypic or phenotypic sensitivity score at base-
line and regardless of whether enfuvirtide, daru-
navir, or both were included in the optimized 
background therapy. Our data provide evidence 
that raltegravir will be a valuable addition to the 
current armamentarium for the treatment of pa-
tients infected with multidrug-resistant HIV-1.
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